

Wireless Micro Current Stimulation (WMCS) - An Innovative Technology for Management of Hard to Heal Wounds

Konstantinos Poulas
Associate Professor,
Department of Pharmacy, University of Patras
GREECE

kpoulas@upatras.gr


IT IS WELL KNOWN THAT THE CURRENT:

Can influence cell functions

Can influence structure and function of molecules


Can influence signal transmission and information
carriage

NEURONS: CELLS THAT PRODUCE ELECTRICAL CURRENT



Konstantinos Poulas, University of Patras,
GREECE


Synapses



- Nerve cells are connected to one another by special electrical circuits known as synapses, which prevent the body's electrical system—the brain, spinal cord and nerves—from being damaged.

Ion channels

Ion channels. When they are open, ions can pass through them, entering or leaving the cell.



Electricity = Drug?

- Modern medicine used to focus for intervention on three main (although not exclusive) approaches:
 - A. surgery,
 - B. irradiation and,
 - C. (Bio)chemistry.
-
- This trinity **does not capitalize** on one modality long known for its key role in many functions in cell and, most important, in whole organism level:
electric currents.


- There is indication enough that **therapeutic use of electric currents or fields (which result in currents) may exert its therapeutic potential at an upstream level** compared to chemicals
- Such protocols may be used uniformly for **multiple ailments** with a common basis; such grouping may be **much larger and more generalized** than similar ones currently attainable by biochemical pharmaceuticals.
- Thus, **the concept of "electroceuticals"** emerges, which is used to describe different modalities, differing in principle, form, quantity, time and other parameters, but focused on administering an external or induced electrical current for amending impaired biological functions.

GSK Bioelectronics

Drug discovery: A jump-start for electroceuticals, [Kristoffer Famm](#), [Brian Litt](#), [Kevin J. Tracey](#), [Edward S. Boyden](#) & [Moncef Slaoui](#) Nature 496, 159–161 (11 April 2013)

IT'S ELECTRIC

Electroceuticals deliver electrical impulses targeting the neural circuits that regulate the body's organs and functions.



To treat disease, an electroceutical homes in on discrete components of the nervous system, such as individual neurons in a specific circuit.

The electroceutical restores health by modulating the action potentials that flow through these neurons.



NEWS



Security update:
Bioelectronics could
give a headstart to
cancer-related therapies.



Designated drugs:
Bioelectronics could
help speed cancer
treatment.



I do declare:
Bioelectronics could
help speed cancer
treatment.

Charged by GSK investment, battery of electroceuticals advances

NEW YORK — When the British biotechnology giant GlaxoSmithKline (GSK) launched its investment in bioelectronics, it was not just to fund the development of the technology, but also to help speed the development of the technology's first products. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.



GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.


GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

GlaxoSmithKline's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits. The company's investment in bioelectronics is part of a broader strategy to develop new therapies for a range of diseases, including cancer, by using electrical impulses to target specific neural circuits.

Electric Cures:

Scientific
American,
March 2015

Konstantinos Poulas, University of Patras, GREECE



Chronology	Accomplishments-events
1st millennium BC	Amber and magnetite (static electrism) used by Egyptians for headache and arthritis.
420 BC	Hippocrates prescribes shocks from torpedo fish
5th c BC	Asklepeia near ionized water environment (falls).
17th c AD	Golden artifacts, charged, to treat smallpox lesions.
1752	Franklinism by Ben Franklin; static electricity to relieve pain.
1800s	Galvanism; DC to relieve pain.
1825	Sarlandiere and Berlioz combine Galvanism ES and acupuncture.
1832	Faradism; use of AC for ES; Duchenne employs it for muscle stimulation.
1850	Publication of the use of ES for bone fractures in US.
1888	D'Arsonvalisation: use of high frequency currents.
1900	Carnage foundation establishes Fleiner committee.
1910	Fleiner results discontinue ES in the US.
1930s	ES modalities actively marketed in Europe.
1944	Galvanic Exercise for wounded personnel of US Armed Forces.
1957	Electric properties of the bone first published by Fukada & Yasuda.
1960s	ES effect on cell wall-principle of electroporation.
1967	Wall &Sweat: 100Hz ES in skin proved analgesic.
1970s	Bruce Lee perfects galvanic exercise for accelerated training.
1980s	Regular ES use in sports injuries and muscle atrophy; discovery of skin battery potentials; antimicrobial effect of ES in vivo, usual treatment of bone fractures.
1982	Cheng et al publish the impact of ES to ATP generation.
1990s	Wound healing by ES becomes prominent.
2000s	Development of NCCT combining different ES schemes' advantages.
2010s	Massive development of different ES schemes and approaches.
2013	Concept of electroceuticals.

Electrical stimulation (ES) is used
(traditionally) for wound healing

Electrical stimulation (ES) is used (traditionally) for wound healing



Difficulties

- I) The electrodes can cause pain
- II) Difficulties in usage
- III) Infection danger
- IV) Can not be used for large wounds

Electrical stimulation (ES) is used (traditionally) for wound healing



Healing of wounds by the use of Electrical Stimulation

“Current of Injury”



Potential difference

Cells of repair

Electric fields in the edge of the wound

In a chronic wound this process is interrupted

LETTERS

Electrical signals control wound healing through phosphatidylinositol-3-OH kinase- γ and PTEN

Min Zhao¹, Bing Song¹, Jin Pu¹, Teiji Wada², Brian Reid¹, Guangping Tai¹, Fei Wang^{3†}, Aihua Guo¹, Petr Walczysko¹, Yu Gu¹, Takehiko Sasaki⁴, Akira Suzuki⁵, John V. Forrester¹, Henry R. Bourne³, Peter N. Devreotes⁶, Colin D. McCaig¹ & Josef M. Penninger²





Figure 1 | Electrical signals direct cell migration in wound healing and activate selected signalling pathways. a, Wounding induces lateral electric fields directed towards the wound centre (red arrow), by collapsing the local transepithelial potential difference (V). Black arrows represent sizes and directions of currents. **b**, Directly measured currents increase over time in

WMCS

Wireless Micro Current Stimulation





Wireless Electrical Stimulation: An Innovative Powerful Tool for the Treatment of a Complicated Chronic Ulcer

Extremity Wounds
XX(X) 1-4
© The Author(s) 2013
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1534734613476111
ijl.sagepub.com
SAGE

Castana Ourania¹, Aekaterini Dimitrouli¹, Theodoros Argyrakos¹,
Emilia Theodorakopoulou², Nektarios Stampolidis¹, Emmanouil Papadopoulos¹,
Athanasios Pallantzis¹, Ioannis Stasinopoulos¹,
and Poulas Konstantinos³



C

D

E





Use of Wireless Microcurrent Stimulation for the Treatment of Diabetes-Related Wounds: 2 Case Reports

Adisaputra Ramadhinara, MD, and Konstantinos Poulas, PhD

ABSTRACT

Wireless microcurrent stimulation (WMCS) is a new method in wound healing that may have advantages compared with conventional electrical stimulation (ES) devices. Although ES has been widely known as an effective method to promote the wound-healing process in patients with type 2 diabetes mellitus, to the authors' knowledge, there are still no data about the ability of WMCS to match the desired effect. In this article, the authors report the results of 2 cases of diabetes-related wounds (1 acute and 1 chronic) that have been treated successfully using WMCS. Neither patient reported discomfort during treatment, and the risk of infection was minimized because there was no direct contact from the device during the treatment course.

KEYWORDS: electrical stimulation and wound healing, microcurrent stimulation, diabetic ulcer, acute and chronic wounds

ADV SKIN WOUND CARE 2013;26:1-4

Clinical experience with a new electrical stimulation (ES) technique, the wireless micro current stimulation (WMCS), for the treatment of chronic wounds is described. WMCS transfers the current to any surface wound from a distance, by using oxygen's and nitrogen's ability to exchange electrons. We studied 47 patients with hard-to-heal wounds. Patients with venous, arterial and mixed leg ulcers were predominant; other aetiologies such as diabetic foot lesions, pressure ulcers, vasculitis and pyoderma were also included. WMCS treatment protocol specified treatment twice or thrice per week, for 45–60 minutes per session, with 1.5 μ A current intensity. Standard wound care was applied to all patients, including compression bandages, if necessary. Clear progress of wound healing, even after 2 weeks, was observed in all cases. The mean reduction of the wound surface after WMCS treatment was 95% in 8 weeks. Complete healing was achieved within 3 months for the majority of the cases. No clinical side effects were observed. WMCS technology significantly accelerated wound healing for patients with hard-to-heal wounds of different aetiologies. This new therapy offers multiple advantages compared with the previous methods of ES, as it is contactless, free of pain and very easy to use.

47 patients

1.5 μ A

95%
reduction in
8 weeks

ORIGINAL ARTICLE

Wireless micro current stimulation – an innovative electrical stimulation method for the treatment of patients with leg and diabetic foot ulcers

Peter G Wirsing¹, Alexander D Habrom¹, Thomas M Zehnder², Sandra Friedli² & Marlise Blatti²

¹ Wundzentrum, Ostalb-Klinikum Aalen, Aalen, Germany

² Angiologie, Spital STS AG Thun, Thun, Switzerland

Key words

Chronic wounds; Diabetic foot; Electrical stimulation; Leg ulcer; Wireless micro current stimulation

Wirsing PG, Habrom AD, Zehnder TM, Friedli S, Blatti M. Wireless micro current stimulation – an innovative electrical stimulation method for the treatment of patients with leg and diabetic foot ulcers. *Int Wound J* 2013; doi: 10.1111/iwj.12204



Figure 9 Wound at (A) treatment start (525 mm²), (B) after 4 weeks (265 mm²) and (C) after 16 weeks (190 mm²).

Wireless micro current stimulation – an innovative electrical stimulation method for the treatment of patients with leg and diabetic foot ulcers

Peter G Wirsing¹, Alexander D Habrom¹, Thomas M Zehnder², Sandra Friedli² & Marlise Blatti²

¹ Wundzentrum, Ostalb-Klinikum Aalen, Aalen, Germany

² Angiologie, Spital STS AG Thun, Thun, Switzerland




Figure 5 Wound at (A) treatment start (875 mm²), (B) after 4 weeks (630 mm²) and (C) after 10 weeks (251 mm²).

OTHER CASES



**1st month of WMCS
therapy**



**4th month of WMCS
therapy**



**12th month of WMCS
therapy**

OTHER CASES

Healing of the wound after 8 days of **WMCS** therapy



**2nd day after
WMCS
therapy**



**4th day after
WMCS
therapy**



**8th day after
WMCS
therapy**

WMCS and Burns

Conference

MOBIHEALTH 2014, Athens Greece

***WIRELESS MICRO CURRENT
STIMULATION TECHNOLOGY
IMPROVES FIREWORK BURN
HEALING.***



Figure 2. Photographs illustrating the burn 1 hour post injury (A) and following WMCS treatment (B, C, D, E, F, G and H). B: Day 2, (after 1 session). C: Day 4 (after 3 sessions), D: Day 5 (after 6 sessions), E: Day 9 (after 8 sessions), F: Day 11 (after 10 sessions), G: 1 week after last WMCS sessions (i.e. 1 week after Day 11), H: 1 month after WMCS sessions.

Charcot Disease (A week after)



Charcot Disease (Two weeks after)

